Morgan Stanley analyst Vikram Purohit maintained a Hold rating on Ascendis Pharma (ASND – Research Report) today and set a price target of ...

Historical trends and future projections of the number of people with overweight and obesity suggest alarming parallel ...

- NDA supported by data from three randomized, double-blind, placebo-controlled clinical trials in children with ...

Ascendis Pharma (ASND) announced that it has submitted its new drug application to the FDA for TransCon CNP for the treatment of children with ...

Ascendis Health has reported an 11. 7% increase in tangible net asset value per share, driven by strong performance in its ...

Healthcare-focused investment company Ascendis reported a climb in its net asset value for its six months to end December, further expressing confidence in its prospects as its restructured businesses ...

Health and wellness investment holding company Ascendis Health increased its net asset value (NAV) by 12% year-on-year to R660-million for the six months ended December 31. The higher NAV was driven ...

According to Benzinga Pro, Ascendis Pharma's peer group average for short interest as a percentage of float is 5.60%, which ...

Ascendis Pharma ASND has outperformed the market over the past 15 years by 20.52% on an annualized basis producing an average annual return of 31.71%. Currently, Ascendis Pharma has a market ...

Ascendis Pharma A/S (NASDAQ:ASND – Get Free Report) last posted its quarterly earnings results on Wednesday, February 12th.The biotechnology company reported ($0.68) earnings per share (EPS) for ...

Visen Phar­ma­ceu­ti­cals, a biotech de­vel­op­ing much of As­cendis Phar­ma’s en­docrine-re­lat­ed dis­ease pipeline for the Chi­na mar­ket, will go pub­lic on the Hong Kong ...